Research-Grade Proteins Market Report 2026

Research-Grade Proteins Market Overview

• Research-Grade Proteins market size has reached to $1.33 billion in 2025 • Expected to grow to $3.19 billion in 2030 at a compound annual growth rate (CAGR) of 18.6% • Growth Driver: Impact Of Clinical Trials On The Research-Grade Proteins Market • Market Trend: Next-Generation Recombinant Proteins Set New Standards for Cell and Gene Therapy Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Research-Grade Proteins Market?

Research-grade proteins refer to proteins that are produced and purified to a high standard of quality and purity for use in scientific research. These proteins are utilized in various experimental and analytical applications, including studies in molecular biology, biochemistry, cell biology, and drug development. They are essential tools for understanding protein function, interaction, structure, and for developing new therapeutic approaches. The main products of research-grade proteins are cytokines and growth factors, antibodies, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory proteins, hormones, and others. Cytokines and growth factors are proteins that regulate cell signaling and immune responses in the body. The host cells including mammalian cells, bacterial cells, fungi and yeast, insect cells, and others used by pharmaceutical and biotechnology companies, academic and research institute, and others.

What Is The Research-Grade Proteins Market Growth Forecast?

The research-grade proteins market size is expected to see rapid growth in the next few years. It will grow to $3.19 billion in 2030 at a compound annual growth rate (CAGR) of 18.6%. The growth in the forecast period can be attributed to increasing focus on precision medicine research, rising demand for protein-based drug targets, growth in cell and gene therapy research, expanding use of proteins in structural biology, increasing outsourcing of research activities by pharma companies. Major trends in the forecast period include rising demand for high-purity proteins in drug discovery research, growing use of recombinant proteins in cell and molecular biology studies, increasing adoption of research-grade proteins in immunology and oncology research, expansion of protein-based assays and functional studies, higher preference for custom and application-specific proteins.

Global Research-Grade Proteins Market Segmentation

1) By Product: Cytokines And Growth Factors, Antibodies, Immune Checkpoint Proteins, Virus Antigens, Enzymes, Recombinant Regulatory Proteins, Hormones, Other Products 2) By Host Cell: Mammalian Cells, Bacterial Cells, Fungi And Yeast, Insect Cells, Other Host Cells 3) By End-Use: Pharmaceutical And Biotechnology Companies, Academic And Research Institute, Other End-Uses Subsegments: 1) By Cytokines And Growth Factors: Interleukins, Interferons, Colony Stimulating Factors, Erythropoietin, Granulocyte Macrophage Colony-Stimulating Factor 2) By Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies, Conjugated Antibodies 3) By Immune Checkpoint Proteins: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors 4) By Virus Antigens: HIV Antigens, Hepatitis Antigens, Influenza Antigens, Hepatitis B Antigens 5) By Enzymes: Restriction Enzymes, Proteases, Ligases, Kinases 6) By Recombinant Regulatory Proteins: Transcription Factors, Regulatory Enzymes, Epigenetic Modifiers 7) By Hormones: Insulin, Thyroid Hormones, Growth Hormones, Adrenaline 8) By Other Products: Peptides, Serum Proteins, Antigen-Binding Proteins

What Is The Driver Of The Research-Grade Proteins Market?

The growing number of clinical trials is expected to propel the growth of the research-grade proteins market. Clinical trials refer to research studies investigating the safety and effectiveness of new medical treatments, interventions, or devices in humans. The number of clinical trials is rising due to medical research advancements, disease burden, regulatory changes, patient demand, and industry investment. Research-grade proteins help in clinical trials by serving as essential tools for biomarker development, assay development, drug target identification, quality control, and reference standards, ensuring the accuracy and reliability of experimental data. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, highlighted that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, the growing number of clinical trials is driving the growth of the research-grade proteins industry.

Key Players In The Global Research-Grade Proteins Market

Major companies operating in the research-grade proteins market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Bio-Techne, Stemcell Technologies Inc., Miltenyi Biotec, GenScript Biotech Corporation, Sino Biological Inc., ACROBiosystems, OriGene Technologies Inc., RayBiotech Inc., Rockland Immunochemicals Inc., Proteintech Group Inc., Novus Biologicals LLC, Active Motif, Aviva Systems Biology Corporation, StressMarq Biosciences Inc., Abnova Corporation, AnaSpec, Biomatik, Prospec-Tany Technogene Ltd., Cusabio Technology LLC, United States Biological, Laurus Bio, Boster Biological Technology, AMS Biotechnology Europe Ltd (AMSBIO)

Global Research-Grade Proteins Market Trends and Insights

Major companies operating in the research-grade proteins market are focusing on developing innovative solutions such as high-purity, animal-origin-free recombinant proteins to improve consistency, safety, and performance in advanced cell and gene therapy workflows. High-purity, animal-origin-free recombinant proteins are lab-made proteins produced without any animal-derived materials and purified to very high standards to ensure consistency, safety, and reliability for research and therapeutic applications. For instance, in October 2025, Qkine Ltd., a UK-based manufacturing company, launched a new range of Cell Therapy Grade recombinant proteins engineered to meet the stringent requirements of cell therapy research, process development, and GMP manufacturing. These high-purity, animal-origin-free proteins offer low endotoxin levels and minimal host cell contaminants and are produced using defined manufacturing standards with complete regulatory documentation. Their consistent performance supports smooth scalability from early research to GMP clinical workflows. Designed for advanced applications such as CAR-T, iPSC differentiation, and ex vivo gene editing, these regulatory-ready proteins help accelerate therapy development while reducing risk.

What Are Latest Mergers And Acquisitions In The Research-Grade Proteins Market?

In December 2023, Danaher Corporation, a US-based science and technology company acquired Abcam plc for approximately $5.7 billion (at $24.00 per share in cash). With this acquisition, Danaher aims to deepen its footprint in the protein consumables market and enhance its technological capabilities in proteomics to accelerate drug discovery and diagnostics. Abcam Limited is a UK-based life‑sciences technology company specializing in highly validated antibodies, reagents, biomarkers, and assays used by researchers globally to study complex biological pathways.

Regional Insights

North America was the largest region in the research-grade proteins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Research-Grade Proteins Market?

The research-grade proteins market consists of sales of bovine serum albumin (BSA), recombinant human insulin, recombinant human epidermal growth factor (EGF), recombinant human tumor necrosis factor-alpha, recombinant human interferon-gamma (IFN-gamma). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Research-Grade Proteins Market Report 2026?

The research-grade proteins market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the research-grade proteins industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.